药学学报, 2021, 56(2): 360-367
引用本文:
李珊, 陈子豪, 吕明, 朱彦. 靶向血小板与肿瘤细胞相互作用药物的现状和未来[J]. 药学学报, 2021, 56(2): 360-367.
LI Shan, CHEN Zi-hao, L� Ming, ZHU Yan. Current status and future of drugs targeting platelets-tumor cells interactions[J]. Acta Pharmaceutica Sinica, 2021, 56(2): 360-367.

靶向血小板与肿瘤细胞相互作用药物的现状和未来
李珊1,2, 陈子豪1,2, 吕明3, 朱彦1,2
1. 天津中医药大学, 省部共建组分中药国家重点实验室, 天津 300193;
2. 天津国际生物医药联合研究院, 中药新药研发中心, 天津 300457;
3. 中国中医科学院中药研究所, 北京 100700
摘要:
血小板与肿瘤细胞的相互作用不仅可以促进恶性肿瘤的转移还可以影响恶性肿瘤相关性血栓的形成。当肿瘤细胞进入血液后,会立即激活血小板,使其黏附于肿瘤细胞表面,保护肿瘤细胞免受血流剪切力和机体免疫系统的攻击,从而促进肿瘤转移;同时,血小板的大量黏附也有可能导致血栓的形成。本文运用生物反应信号网络分析(ingenuity pathway analysis,IPA)和文献整合的方法探究了血小板与肿瘤细胞相互作用的机制,以及针对血小板与肿瘤细胞的相互作用治疗恶性肿瘤转移的潜在药物,为今后基于其作用机制来开发靶向血小板与肿瘤细胞相互作用的新药提供了一定的理论依据和临床参考。
关键词:    血小板      肿瘤细胞      相互作用      肿瘤转移      潜在药物     
Current status and future of drugs targeting platelets-tumor cells interactions
LI Shan1,2, CHEN Zi-hao1,2, L� Ming3, ZHU Yan1,2
1. State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China;
2. Chinese Medicine New Drug Research and Development Center, Tianjin International Biomedical Research Institute, Tianjin 300457, China;
3. Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China
Abstract:
The interaction between platelets and tumor cells can not only promote the metastasis of malignant tumors, but also affect the formation of malignant tumor-related thrombus. When tumor cells enter the blood, they will immediately activate platelets to make them adhere to the surface of tumor cells, protecting tumor cells from blood flow shear force and immune system attack, thereby promoting tumor metastasis. At the same time, the massive adhesion of platelets may also lead to the formation of thrombus. In this article, we use the methods of ingenuity pathway analysis and literature integration to explore the mechanism of platelet-tumor cell interaction and potential drugs for the treatment of malignant tumor metastasis based on the platelet-tumor cell interaction. It provides a certain theoretical basis and clinical reference for the future development of new drugs targeting platelet-tumor cell interaction based on its mechanism of action.
Key words:    platelet    tumor cell    interaction    tumor metastasis    potential drug   
收稿日期: 2020-07-07
DOI: 10.16438/j.0513-4870.2020-1122
基金项目: 国家自然科学基金资助项目(81873037);国家重点研发计划(2018YFC1704502).
通讯作者: 朱彦,Tel:15822700439,Fax:86-22-27429103,E-mail:yanzhu.harvard@icloud.com
Email: yanzhu.harvard@icloud.com
相关功能
PDF(1002KB) Free
打印本文
0
作者相关文章
李珊  在本刊中的所有文章
陈子豪  在本刊中的所有文章
吕明  在本刊中的所有文章
朱彦  在本刊中的所有文章

参考文献:
[1] Plantureux L, Mège D, Crescence L, et al. Impacts of cancer on platelet production, activation and education and mechanisms of cancer-associated thrombosis[J]. Cancers (Basel), 2018, 10:441.
[2] Wang S, Li Z, Xu R. Human cancer and platelet interaction, a potential therapeutic target[J]. Int J Mol Sci, 2018, 19:1246.
[3] Benkli K. PO-35-designing of the new antithrombotic and also anticancer gold complexes[J]. Thromb Res, 2016, 140 Suppl 1:S189.
[4] Zhang C, Srinivasan Y, Arlow DH, et al. High-resolution crystal structure of human protease-activated receptor 1[J]. Nature, 2012, 492:387-392.
[5] Boire A, Covic L, Agarwal A, et al. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells[J]. Cell, 2005, 120:303-313.
[6] Deng QP, Wang MJ, Zeng X, et al. Effects of glycyrrhizin in a mouse model of lung adenocarcinoma[J]. Cell Physiol Biochem, 2017, 41:1383-1392.
[7] Gore JM, Appelbaum JS, Greene HL, et a1. Occult cancer in patients with acute pulmonary embolism[J]. Ann Intern Med, 1982, 96:556-560.
[8] Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism:a 25-year population-based study[J]. Arch Intern Med, 1998, 158:585-593.
[9] Yu LX, Yan L, Yang W, et al. Platelets promote tumour metastasis via interaction between TLR4 and tumour cell-released high-mobility group box1 protein[J]. Nat Commun, 2014, 5:5256.
[10] Mammadova-Bach E, Zigrino P, Brucker C, et al. Platelet integrin α6β1 controls lung metastasis through direct binding to cancer cell-derived ADAM9[J]. JCI Insight, 2016, 1:e88245.
[11] Tsukiji N, Inoue O, Morimoto M, et al. Platelets play an essential role in murine lung development through Clec-2/podoplanin interaction[J]. Blood, 2018, 132:1167-1179.
[12] Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development[J]. Arterioscler Thromb Vasc Biol, 2004, 24:1015-1022.
[13] Wang J, Xiao J, Wen D, et al. Endothelial cell-anchored tissue factor pathway inhibitor regulates tumor metastasis to the lung in mice[J]. Mol Carcinog, 2016, 55:882-896.
[14] Ruf W, Yokota N, Schaffner F. Tissue factor in cancer progression and angiogenesis[J]. Thromb Res, 2010, 125 Suppl 2:S36-S38.
[15] Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis[J]. Nat Rev Cancer, 2011, 11:123-134.
[16] Li N. Platelets in cancer metastasis:to help the "villain" to do evil[J]. Int J Cancer, 2016, 138:2078-2087.
[17] Golebiewska EM, Poole AW. Platelet secretion:from haemostasis to wound healing and beyond[J]. Blood Rev, 2015, 29:153-162.
[18] Läubli H, Borsig L. Selectins as mediators of lung metastasis[J]. Cancer Microenviron, 2010, 3:97-105.
[19] Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis[J]. Cancer Cell, 2011, 20:576-590.
[20] Elaskalani O, Berndt MC, Falasca M, et al. Targeting platelets for the treatment of cancer[J]. Cancers (Basel), 2017, 9:94.
[21] Egan K, Cooke N, Kenny D. Living in shear:platelets protect cancer cells from shear induced damage[J]. Clin Exp Metastasis, 2014, 31:697-704.
[22] Hilgard P. The role of blood platelets in experimental metastases[J]. Br J Cancer, 1973, 28:429-435.
[23] Seyfried TN, Huysentruyt LC. On the origin of cancer metastasis[J]. Crit Rev Oncog, 2013, 18:43-73.
[24] Gresele P, Malvestiti M, Momi S. Anti-platelet treatments in cancer:basic and clinical research[J]. Thromb Res, 2018,164 Suppl 1:S106-S111.
[25] Xiong YQ, Li XJ. Common risk factors of cardiovascular diseases and malignant tumors and the influence of drugs[J]. Acta Pharm Sin (药学学报), 2020, 55:1-7.
[26] Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality:20-year follow-up of five randomised trials[J]. Lancet, 2010, 376:1741-1750.
[27] Ornelas A, Zacharias-Millward N, Menter DG, et al. Beyond COX-1:the effects of aspirin on platelet biology and potential mechanisms of chemoprevention[J]. Cancer Metastasis Rev, 2017, 36:289-303.
[28] Wang Y, Sun Y, Li D, et al. Platelet P2Y12 is involved in murine pulmonary metastasis[J]. PLoS One, 2013, 8:e80780.
[29] Gebremeskel S, LeVatte T, Liwski RS, et al. The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer[J]. Int J Cancer, 2015, 136:234-240.
[30] Gareau AJ, Brien C, Gebremeskel S, et al. Ticagrelor inhibits platelet-tumor cell interactions and metastasis in human and murine breast cancer[J]. Clin Exp Metastasis, 2018, 35:25-35.
[31] Braganhol E, Morrone FB, Bernardi A, et al. Selective NTPDase2 expression modulates in vivo rat glioma growth[J]. Cancer Sci, 2009, 100:1434-1442.
[32] Bambace NM, Levis JE, Holmes CE. The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets[J]. Platelets, 2010, 21:85-93.
[33] Uzawa K, Kasamatsu A, Baba T, et al. Targeting phosphodiesterase 3B enhances cisplatin sensitivity in human cancer cells[J]. Cancer Med, 2013, 2:40-49.
[34] Okoshi H, Hakomori S, Nisar M, et al. Cell membrane signaling as target in cancer therapy II:inhibitory effect of N,N,N-trimethylsphingosine on metastatic potential of murine B16 melanoma cell line through blocking of tumor cell-dependent platelet aggregation[J]. Cancer Res, 1991, 51:6019-6024.
[35] Desai PB, Duan J, Sridhar R, et al. Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole[J]. Methods Find Exp Clin Pharmacol, 1997, 19:231-239.
[36] Spano D, Marshall JC, Marino N, et al. Dipyridamole prevents triple-negative breast-cancer progression[J]. Clin Exp Metastasis, 2013, 30:47-68.
[37] Li XX, Ma YF, Li GD, et al. The pathogenesis of hypercoagulable state of malignant tumors and the progress of traditional Chinese and Western medicine treatment[J]. World J Integr Tradit West Med (世界中西医结合杂志), 2019, 14:1619-1623.
[38] Zhang PT, Park BK. Blood stasis syndrome and malignant tumors[J]. Chin J Surg Integr Tradit West Med (中国中西医结合外科杂志), 1998, 4:378.
[39] Lin WF, Lu JY, Cheng BB, et al. Progress in research on the effects of traditional Chinese medicine on the tumor microenvironment[J]. J Integr Med, 2017, 15:282-287.
[40] Zhu YC, Xu XF, Li W. Advances in research on promoting blood circulation and removing blood stasis and tumor treatment[J]. Asia Pacific Tradit Med (亚太传统医药), 2019, 15:182-185.
[41] Takagi S, Tsukamoto S, Park J, et al. Platelets enhance multiple myeloma progression via IL-1β upregulation[J]. Clin Cancer Res, 2018, 24:2430-2439.
[42] Labelle M, Begum S. Platelets guide the formation of early metastatic niches[J]. Proc Natl Acad Sci U S A, 2014, 111:E3053-E3061.
[43] Häuselmann I, Roblek M, Protsyuk D, et al. Monocyte induction of E-selectin-mediated endothelial activation releases VE-cadherin junctions to promote tumor cell extravasation in the metastasis cascade[J]. Cancer Res, 2016, 76:5302-5312.
[44] Han H, Wang XW. Research progress of tumor platelet-related angiogenesis regulatory protein[J]. Chin J Cancer Prevent Treat (中华肿瘤防治杂志), 2018, 25:1045-1050.
[45] Wang S, Yu Y, Ryan PM, et al. Association of aspirin therapy with risk of hepatocellular carcinoma:a systematic review and dose-response analysis of cohort studies with 2.5 million participants[J]. Pharmacol Res, 2020, 151:104585.
相关文献:
1.张倩, 居文政, 郭建明, 李建萍, 姚毅, 唐志书, 赵步长, 段金廒.头孢曲松改变丹红注射液酚酸类成分在大鼠体内药动学行为和抗凝血抗血栓药效的研究[J]. 药学学报, 2019,54(4): 701-709